279 related articles for article (PubMed ID: 24962630)
21. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
Valladares JE; Alberola J; Esteban M; Arboix M
Vet Rec; 1996 Feb; 138(8):181-3. PubMed ID: 8677619
[TBL] [Abstract][Full Text] [Related]
22. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
Chapman WL; Hanson WL; Alving CR; Hendricks LD
Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
[TBL] [Abstract][Full Text] [Related]
23. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
da Costa-Silva TA; Galisteo AJ; Lindoso JA; Barbosa LR; Tempone AG
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of clinical and laboratory findings of adult visceral leishmaniasis cases].
Ural S; Kaptan F; Sezak N; El S; Örmen B; Türker N; Demirdal T; Vardar İ; Özkan Çayıröz P; Çakalağaoğlu F
Mikrobiyol Bul; 2015 Oct; 49(4):586-93. PubMed ID: 26649416
[TBL] [Abstract][Full Text] [Related]
25. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
[TBL] [Abstract][Full Text] [Related]
26. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size.
Schettini DA; Ribeiro RR; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Int J Pharm; 2006 Jun; 315(1-2):140-7. PubMed ID: 16549281
[TBL] [Abstract][Full Text] [Related]
27. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
28. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
Mendonça DVC; Martins VT; Lage DP; Dias DS; Ribeiro PAF; Carvalho AMRS; Dias ALT; Miyazaki CK; Menezes-Souza D; Roatt BM; Tavares CAP; Barichello JM; Duarte MC; Coelho EAF
Exp Parasitol; 2018 Mar; 186():24-35. PubMed ID: 29448040
[TBL] [Abstract][Full Text] [Related]
29. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
30. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
31. Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial.
Medkour H; Bitam I; Laidoudi Y; Lafri I; Lounas A; Hamidat HK; Mekroud A; Varloud M; Davoust B; Mediannikov O
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008947. PubMed ID: 33338041
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
Oliva G; Gradoni L; Cortese L; Orsini S; Ciaramella P; Scalone A; de Luna R; Persechino A
Ann Trop Med Parasitol; 1998 Mar; 92(2):165-71. PubMed ID: 9625912
[TBL] [Abstract][Full Text] [Related]
33. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
[TBL] [Abstract][Full Text] [Related]
34. Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.
Gangneux JP; Dullin M; Sulahian A; Garin YJ; Derouin F
Antimicrob Agents Chemother; 1999 Jan; 43(1):172-4. PubMed ID: 9869587
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the cardiac toxicity of N-methyl-glucamine antimoniate in dogs with naturally occurring leishmaniasis.
Luciani A; Sconza S; Civitella C; Guglielmini C
Vet J; 2013 Apr; 196(1):119-21. PubMed ID: 23021954
[TBL] [Abstract][Full Text] [Related]
36. Liposomal resiquimod for the treatment of Leishmania donovani infection.
Peine KJ; Gupta G; Brackman DJ; Papenfuss TL; Ainslie KM; Satoskar AR; Bachelder EM
J Antimicrob Chemother; 2014 Jan; 69(1):168-75. PubMed ID: 23956375
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
[TBL] [Abstract][Full Text] [Related]
38. Effects of therapy on haemostasis in dogs infected with Leishmania infantum, Ehrlichia canis, or both combined.
Cortese L; Pelagalli A; Piantedosi D; Cestaro A; Di Loria A; Lombardi P; Avallone L; Ciaramella P
Vet Rec; 2009 Apr; 164(14):433-4. PubMed ID: 19346544
[No Abstract] [Full Text] [Related]
39. Novel methods for the encapsulation of meglumine antimoniate into liposomes.
Frézard F; Michalick MS; Soares CF; Demicheli C
Braz J Med Biol Res; 2000 Jul; 33(7):841-6. PubMed ID: 10881061
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]